Dyne Therapeutics Inc has a consensus price target of $37.38, established from looking at the 20 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, Chardan Capital, and Guggenheim on March 26, 2024, March 8, 2024, and March 7, 2024. With an average price target of $38.33 between Oppenheimer, Chardan Capital, and Guggenheim, there's an implied 34.50% upside for Dyne Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/26/2024 | DYN | Buy Now | Dyne Therapeutics | $28.50 | 64.91% | Oppenheimer | Francois Brisebois | $47 → $47 | Reiterates | Outperform → Outperform | Get Alert |
03/08/2024 | DYN | Buy Now | Dyne Therapeutics | $28.50 | 8.77% | Chardan Capital | Keay Nakae | $20 → $31 | Maintains | Buy | Get Alert |
03/07/2024 | DYN | Buy Now | Dyne Therapeutics | $28.50 | 29.82% | Guggenheim | Debjit Chattopadhyay | $33 → $37 | Maintains | Buy | Get Alert |
03/06/2024 | DYN | Buy Now | Dyne Therapeutics | $28.50 | 26.32% | HC Wainwright & Co. | Andrew Fein | → $36 | Reiterates | Buy → Buy | Get Alert |
03/06/2024 | DYN | Buy Now | Dyne Therapeutics | $28.50 | 43.86% | Stifel | Paul Matteis | $35 → $41 | Maintains | Buy | Get Alert |
03/06/2024 | DYN | Buy Now | Dyne Therapeutics | $28.50 | 1.75% | Piper Sandler | Edward Tenthoff | $27 → $29 | Maintains | Overweight | Get Alert |
03/05/2024 | DYN | Buy Now | Dyne Therapeutics | $28.50 | 64.91% | Oppenheimer | Francois Brisebois | $44 → $47 | Reiterates | Outperform → Outperform | Get Alert |
02/20/2024 | DYN | Buy Now | Dyne Therapeutics | $28.50 | 26.32% | HC Wainwright & Co. | Andrew Fein | → $36 | Initiates | → Buy | Get Alert |
01/04/2024 | DYN | Buy Now | Dyne Therapeutics | $28.50 | 96.49% | Raymond James | Steven Seedhouse | $27 → $56 | Maintains | Strong Buy | Get Alert |
08/09/2023 | DYN | Buy Now | Dyne Therapeutics | $28.50 | -22.81% | JP Morgan | Tessa Romero | $20 → $22 | Maintains | Overweight | Get Alert |
08/04/2023 | DYN | Buy Now | Dyne Therapeutics | $28.50 | -29.82% | Chardan Capital | Keay Nakae | → $20 | Reiterates | Buy → Buy | Get Alert |
03/03/2023 | DYN | Buy Now | Dyne Therapeutics | $28.50 | -29.82% | Chardan Capital | Keay Nakae | $17 → $20 | Maintains | Buy | Get Alert |
02/27/2023 | DYN | Buy Now | Dyne Therapeutics | $28.50 | -5.26% | Raymond James | Steven Seedhouse | $16 → $27 | Upgrade | Outperform → Strong Buy | Get Alert |
02/15/2023 | DYN | Buy Now | Dyne Therapeutics | $28.50 | 19.3% | Oppenheimer | Francois Brisebois | → $34 | Initiates | → Outperform | Get Alert |
01/26/2023 | DYN | Buy Now | Dyne Therapeutics | $28.50 | 15.79% | Guggenheim | Debjit Chattopadhyay | → $33 | Initiates | → Buy | Get Alert |
11/29/2022 | DYN | Buy Now | Dyne Therapeutics | $28.50 | -36.84% | JP Morgan | Tessa Romero | $24 → $18 | Maintains | Overweight | Get Alert |
11/04/2022 | DYN | Buy Now | Dyne Therapeutics | $28.50 | -43.86% | Raymond James | Steven Seedhouse | $15 → $16 | Maintains | Outperform | Get Alert |
07/20/2022 | DYN | Buy Now | Dyne Therapeutics | $28.50 | -40.35% | Chardan Capital | Keay Nakae | → $17 | Initiates | → Buy | Get Alert |
07/12/2022 | DYN | Buy Now | Dyne Therapeutics | $28.50 | -47.37% | Raymond James | Steven Seedhouse | → $15 | Initiates | → Outperform | Get Alert |
The latest price target for Dyne Therapeutics (NASDAQ: DYN) was reported by Oppenheimer on March 26, 2024. The analyst firm set a price target for $47.00 expecting DYN to rise to within 12 months (a possible 63.99% upside). 11 analyst firms have reported ratings in the last year.
The latest analyst rating for Dyne Therapeutics (NASDAQ: DYN) was provided by Oppenheimer, and Dyne Therapeutics reiterated their outperform rating.
The last upgrade for Dyne Therapeutics Inc happened on February 27, 2023 when Raymond James raised their price target to $27. Raymond James previously had an outperform for Dyne Therapeutics Inc.
There is no last downgrade for Dyne Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dyne Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dyne Therapeutics was filed on March 26, 2024 so you should expect the next rating to be made available sometime around March 26, 2025.
While ratings are subjective and will change, the latest Dyne Therapeutics (DYN) rating was a reiterated with a price target of $47.00 to $47.00. The current price Dyne Therapeutics (DYN) is trading at is $28.66, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.